Fate Therapeutics (FATE) Change in Receivables (2018 - 2026)

Fate Therapeutics (FATE) has 8 years of Change in Receivables data on file, last reported at -$212000.0 in Q1 2026.

• Quarterly Change in Receivables rose 81.31% year-over-year to -$212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 279.73% YoY) and the FY2025 annual result came in at -$2.6 million, down 335.76% from the prior year.
• Change in Receivables slipped to -$212000.0 in Q1 2026, from $233000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $28.3 million in Q4 2022 to a low of -$25.0 million in Q1 2023.
• A 5-year average of -$504294.1 and a median of -$713000.0 in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables soared 1970.11% — and 2023, when it sank 1373.2%.
• Tracing FATE's Change in Receivables over 5 years: stood at $28.3 million in 2022, then tumbled by 98.98% to $288000.0 in 2023, then tumbled by 304.17% to -$588000.0 in 2024, then soared by 139.63% to $233000.0 in 2025, then sank by 190.99% to -$212000.0 in 2026.
• The last three Change in Receivables figures came in at -$212000.0 (Q1 2026), $233000.0 (Q4 2025), and -$713000.0 (Q3 2025), per Business Quant data.